Apellis Pharma Files 8-K on Operations & Financial Condition
Ticker: APLS · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1492422
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-update
TL;DR
**APLS filed an 8-K on Jan 8, 2024, updating on operations and financials.**
AI Summary
Apellis Pharmaceuticals, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is managing its finances and operating, directly impacting their investment's value.
Why It Matters
This filing provides an update on Apellis Pharmaceuticals' financial health, which is essential for investors to assess the company's performance and make informed decisions about their stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently signal new risks, but rather provides data for risk assessment.
Analyst Insight
A smart investor would review the detailed financial statements and results of operations once they become available to understand the specific financial performance and outlook of Apellis Pharmaceuticals, Inc. This filing itself is a procedural update, signaling that more detailed financial information is either being provided or will be provided soon.
Key Numbers
- 001-38276 — Commission File Number (Identifies the company's registration with the SEC.)
- 20240108 — Conformed Period of Report (Indicates the specific date the report covers.)
Key Players & Entities
- Apellis Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- 001-38276 (dollar_amount) — Commission File Number
- January 8, 2024 (date) — Date of earliest event reported and filing date
- Nasdaq Global Select Market (company) — exchange where Common Stock is registered
- APLS (company) — trading symbol for Common Stock
FAQ
What is the purpose of this 8-K filing by Apellis Pharmaceuticals, Inc.?
The purpose of this 8-K filing, dated January 8, 2024, is to report on the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' of Apellis Pharmaceuticals, Inc., as indicated by the 'ITEM INFORMATION' sections.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.
What is the trading symbol and exchange for Apellis Pharmaceuticals, Inc.'s common stock?
Apellis Pharmaceuticals, Inc.'s Common Stock trades under the symbol 'APLS' on the 'Nasdaq Global Select Market', according to the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of Apellis Pharmaceuticals, Inc.?
The business address for Apellis Pharmaceuticals, Inc. is 100 Fifth Avenue, Waltham, MA 02451, and their telephone number is (617) 977-5700, as listed in the 'BUSINESS ADDRESS' section.
Is Apellis Pharmaceuticals, Inc. considered an emerging growth company?
The filing indicates with a checkbox '☐' that Apellis Pharmaceuticals, Inc. is NOT checking the box for being an emerging growth company, meaning it does not consider itself one as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 593 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-01-08 09:07:01
Filing Documents
- d51181d8k.htm (8-K) — 25KB
- d51181dex991.htm (EX-99.1) — 39KB
- g51181g0107221249788.jpg (GRAPHIC) — 2KB
- 0001193125-24-003998.txt ( ) — 192KB
- apls-20240108.xsd (EX-101.SCH) — 3KB
- apls-20240108_lab.xml (EX-101.LAB) — 17KB
- apls-20240108_pre.xml (EX-101.PRE) — 11KB
- d51181d8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition On January 8, 2024, Apellis Pharmaceuticals, Inc. (the "Company") issued a press release announcing preliminary unaudited total U.S. net product revenues and net product revenue for SYFOVRE and EMPAVELI for the fourth quarter and full year ended December 31, 2023. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company's U.S. net product revenue figures are preliminary and unaudited, represent management's estimate as of the date of this report and are subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company's net product revenue figures. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apellis Pharmaceuticals, Inc. Date: January 8, 2024 By: /s/ Timothy Sullivan Timothy Sullivan Chief Financial Officer